Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Cue Biopharma (NASDAQ:CUE) but lowers the price target from $8 to $3.
July 26, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler's analyst Edward Tenthoff maintains an Overweight rating on Cue Biopharma but significantly lowers the price target from $8 to $3.
The significant reduction in the price target from $8 to $3 suggests a less optimistic outlook for Cue Biopharma's future performance, which is likely to negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100